HR and breast carcinoma: CDK 4/6 inhibitors that have been FDA-approved for the treatment of HR+, HER2− breast cancer (palbociclib, abemaciclib, ribociclib) are also being examined for their efficacy in the treatment of HER2+ disease, with numerous ongoing clinical trials.